Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

Recruiting

Phase 1

Lutetium Lu 177 EdotreotidePhase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

Sponsor:

ITM Solucin GmbH

Code:

NCT06441331

Conditions

Somatostatin Receptor Positive

NETs

Lymphoma

Solid Tumor

CNS Tumors

Eligibility Criteria

Sex: All

Age: 2 - 18

Healthy Volunteers: Not accepted

Interventions

Lutetium Lu 177-Edotreotide

Amino Acid Solution

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-12-26. This information was provided to ClinicalTrials.gov by ITM Solucin GmbH on 2025-12-17.